Alnylam Pharmaceuticals Inc to Discuss Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran - Corporate Call Transcript - Thomson StreetEvents

Alnylam Pharmaceuticals Inc to Discuss Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran - Corporate Call Transcript

Alnylam Pharmaceuticals Inc to Discuss Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran - Corporate Call Transcript - Thomson StreetEvents
Alnylam Pharmaceuticals Inc to Discuss Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran - Corporate Call Transcript
Published Apr 19, 2021
19 pages (11473 words) — Published Apr 19, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of ALNY.OQ conference call or presentation 19-Apr-21 8:00pm GMT

  
Brief Excerpt:

...Operator Ladies and gentlemen, thank you for standing by. Welcome to the Alnylam Pharmaceuticals Conference Call to discuss 9-month results from the HELIOS-A Phase III study. (Operator Instructions) Please be advised that this call is being taped at the company's request. I would now like to turn the call over to the company. Christine Regan Lindenboom ...

  
Report Type:

Transcript

Source:
Company:
Alnylam Pharmaceuticals Inc
Ticker
ALNY.OQ
Time
8:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

Alnylam Pharmaceuticals Inc Annual Shareholders Meeting Transcript – 2021-05-18 – US$ 54.00 – Edited Transcript of ALNY.OQ shareholder or annual meeting 18-May-21 2:30pm GMT

Alnylam Pharmaceuticals Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript – 2021-05-11 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 11-May-21 6:45pm GMT

Alnylam Pharmaceuticals Inc Q1 2021 Earnings Call Summary – 2021-04-29 – US$ 54.00 – Edited Brief of ALNY.OQ earnings conference call or presentation 29-Apr-21 12:30pm GMT

Alnylam Pharmaceuticals Inc Q1 2021 Earnings Call Transcript – 2021-04-29 – US$ 54.00 – Edited Transcript of ALNY.OQ earnings conference call or presentation 29-Apr-21 12:30pm GMT

Alnylam Pharmaceuticals Inc to Discuss Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran - Corporate Call Summary – 2021-04-19 – US$ 54.00 – Edited Brief of ALNY.OQ conference call or presentation 19-Apr-21 8:00pm GMT

Alnylam Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript – 2021-04-13 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 13-Apr-21 5:30pm GMT

Alnylam Pharmaceuticals Inc at Stifel CNS Day Transcript – 2021-04-01 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 1-Apr-21 3:00pm GMT

Alnylam Pharmaceuticals Inc at Barclays Global Healthcare Conference (Virtual) Transcript – 2021-03-10 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 10-Mar-21 6:15pm GMT

Alnylam Pharmaceuticals Inc at H C Wainwright Global Life Sciences Conference (Virtual) Transcript – 2021-03-09 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 9-Mar-21 12:00pm GMT

Alnylam Pharmaceuticals Inc at Cowen Healthcare Conference (Virtual) Transcript – 2021-03-01 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 1-Mar-21 7:40pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Alnylam Pharmaceuticals Inc to Discuss Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran - Corporate Call Transcript" Apr 19, 2021. Alacra Store. May 03, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Alnylam-Pharmaceuticals-Inc-to-Discuss-Full-9-Month-Results-from-the-HELIOS-A-Phase-3-Study-of-Vutrisiran-Corporate-Call-T14635988>
  
APA:
Thomson StreetEvents. (2021). Alnylam Pharmaceuticals Inc to Discuss Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran - Corporate Call Transcript Apr 19, 2021. New York, NY: Alacra Store. Retrieved May 03, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Alnylam-Pharmaceuticals-Inc-to-Discuss-Full-9-Month-Results-from-the-HELIOS-A-Phase-3-Study-of-Vutrisiran-Corporate-Call-T14635988>
  
US$ 54.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.